Portal de Periódicos da CAPES

Female sex and autoimmune hepatitis and the risk of portopulmonary hypertension

2008; Lippincott Williams & Wilkins; Volume: 48; Issue: 6 Linguagem: Inglês

10.1002/hep.22599

1527-3350

Gustavo Castaño, Silvia Sookoian,

Pulmonary Hypertension Research and Treatments

We read with great interest the article by Kawut et al. regarding the clinical risk factors for portopulmonary hypertension (PPHTN) in a multicenter case-control epidemiologic study.1 The authors demonstrated that women with liver disease have a higher risk than men of developing PPHTN. They have also showed that the cause of liver disease is important in determining the risk of this serious pulmonary vascular complication. In a series of 90 outpatients with cirrhosis without portal thrombosis, we evaluated the presence of PPHTN by right heart catheterization with a Swan-Ganz catheter under fluoroscopic guidance and analyzed the relationship between hemodynamic parameters and the cause of liver disease. Patients showed a mean age of 52 years (19-72); 60 patients were Child-Pugh class A, 18 class B, and 12 class C. The study methodology was described elsewhere.2 Eight of 90 patients showed mean pulmonary artery pressure (mPAP) higher than 25 mmHg. However, only two patients fulfilled the criteria of PPHTN as described by Kawut et al.1 Therefore, the prevalence of this entity in our population was 2.2%. Interestingly, the two patients with PPHTN were young women, aged 19 and 30 years, respectively, having autoimmune hepatitis. In the whole sample, patients with autoimmune hepatitis or primary biliary cirrhosis were mostly women (13/15), and they were younger [44 ± 15 standard deviations (SD) versus 54 ± 9 SD years; P = 0.001] and showed higher mPAP (22.5 ± 8.8 SD versus 17.9 ± 7.2 SD mmHg; P = 0.03) and pulmonary vascular resistance (246 ± 209 SD versus143 ± 63 SD dyn · second/cm5; P = 0.008) than patients with cirrhosis of other causes (Table 1). In addition, pulmonary vascular resistance was significantly higher in women compared with men (193.5 ± 161.9 SD versus 133.4 ± 58.9 SD SD dyn · second/cm5, respectively, P < 0.05), regardless of the cause of liver disease. Conversely, patients with hepatitis C showed lower mPAP than other causes (16.3 ± 5 SD versus 19.8 ± 8 SD, P = 0.04). No correlation was found between mPAP and other portal or systemic hemodynamic parameter or with severity of liver disease, but a negative correlation was found with age (r = −0.28; P < 0.05). In summary, in agreement with Kawut et al., we also observed that young women with autoimmune hepatitis might have an increased risk of developing PPHTN in comparison with patients with advanced liver disease of other causes. In addition, our patients with PPHTN showed lower scores of Child-Pugh classification, suggesting that the severity of liver disease is not a good predictor of PPHTN. Hence, these findings support the hypothesis that other factors nonrelated to hemodynamic changes present in portal hypertension and cirrhosis may play a role in the pathogenesis of PPHTN. Gustavo Castaño MD, PhD* , Silvia Sookoian MD, PhD* , * Department of Medicine & Surgery. Hospital Abel Zubizarreta. Ciudad Autónoma de Buenos Aires, Argentina, Research Council of GCBA, Ciudad Autónoma de Buenos Aires, Argentina, Laboratory of Clinical and Molecular Hepatology. Department of Molecular Genetics and Biology of Complex Diseases. Institute of Medical Research, University of Buenos Aires-CONICET. Ciudad Autónoma de Buenos Aires, Argentina.